Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1585 to 1596 of 1616 entries
Sorted by: Best Match Show Resources per page
A year in heart failure: an update of recent findings.

ESC heart failure

Stretti L, Zippo D, Coats AJS, Anker MS, von Haehling S, Metra M, Tomasoni D.
PMID: 34918477
ESC Heart Fail. 2021 Dec;8(6):4370-4393. doi: 10.1002/ehf2.13760. Epub 2021 Dec 16.

Major changes have occurred in these last years in heart failure (HF) management. Landmark trials and the 2021 European Society of Cardiology guidelines for the diagnosis and treatment of HF have established four classes of drugs for treatment of...

Cite
Stretti L, Zippo D, Coats AJS, et al. A year in heart failure: an update of recent findings. ESC Heart Fail. 2021;8(6):4370-4393doi: 10.1002/ehf2.13760.
Stretti, L., Zippo, D., Coats, A. J. S., Anker, M. S., von Haehling, S., Metra, M., & Tomasoni, D. (2021). A year in heart failure: an update of recent findings. ESC heart failure, 8(6), 4370-4393. https://doi.org/10.1002/ehf2.13760
Stretti, Lorenzo, et al. "A year in heart failure: an update of recent findings." ESC heart failure vol. 8,6 (2021): 4370-4393. doi: https://doi.org/10.1002/ehf2.13760
Stretti L, Zippo D, Coats AJS, Anker MS, von Haehling S, Metra M, Tomasoni D. A year in heart failure: an update of recent findings. ESC Heart Fail. 2021 Dec;8(6):4370-4393. doi: 10.1002/ehf2.13760. Epub 2021 Dec 16. PMID: 34918477.
Copy Download .nbib Format: NLM
Incremental value of left ventricular shape parameters measured by gated SPECT MPI in predicting the super-response to CRT.

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology

He Z, de Amorim Fernandes F, do Nascimento EA, Garcia EV, Mesquita CT, Zhou W.
PMID: 33506382
J Nucl Cardiol. 2021 Jan 27; doi: 10.1007/s12350-020-02469-7. Epub 2021 Jan 27.

BACKGROUND: The purpose of this study was to evaluate the predictive value of left ventricular (LV) shape parameters measured by gated SPECT myocardial perfusion imaging (MPI) in super-responders enrolled in the VISION-CRT trial.METHODS: One hundred and ninety-nine patients who...

Cite
He Z, de Amorim Fernandes F, do Nascimento EA, et al. Incremental value of left ventricular shape parameters measured by gated SPECT MPI in predicting the super-response to CRT. J Nucl Cardiol. 2021;doi: 10.1007/s12350-020-02469-7.
He, Z., de Amorim Fernandes, F., do Nascimento, E. A., Garcia, E. V., Mesquita, C. T., & Zhou, W. (2021). Incremental value of left ventricular shape parameters measured by gated SPECT MPI in predicting the super-response to CRT. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, . https://doi.org/10.1007/s12350-020-02469-7
He, Zhuo, et al. "Incremental value of left ventricular shape parameters measured by gated SPECT MPI in predicting the super-response to CRT." Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology vol. (2021). doi: https://doi.org/10.1007/s12350-020-02469-7
He Z, de Amorim Fernandes F, do Nascimento EA, Garcia EV, Mesquita CT, Zhou W. Incremental value of left ventricular shape parameters measured by gated SPECT MPI in predicting the super-response to CRT. J Nucl Cardiol. 2021 Jan 27; doi: 10.1007/s12350-020-02469-7. Epub 2021 Jan 27. PMID: 33506382.
Copy Download .nbib Format: NLM
Captopril and losartan attenuate behavioural sensitization in mice chronically exposed to toluene.

Behavioural brain research

Oros-González A, Gallardo-Ortíz IA, Montes S, Del Valle-Mondragón L, Páez-Martínez N.
PMID: 34757000
Behav Brain Res. 2022 Feb 10;418:113640. doi: 10.1016/j.bbr.2021.113640. Epub 2021 Oct 29.

Inhalants are consumed worldwide for recreational purposes. The main component found in many inhalants is toluene. One of the most deleterious behavioural effects caused by chronic exposure to inhalants is addiction. This response has been associated with activation of...

Cite
Oros-González A, Gallardo-Ortíz IA, Montes S, et al. Captopril and losartan attenuate behavioural sensitization in mice chronically exposed to toluene. Behav Brain Res. 2021;418:113640doi: 10.1016/j.bbr.2021.113640.
Oros-González, A., Gallardo-Ortíz, I. A., Montes, S., Del Valle-Mondragón, L., & Páez-Martínez, N. (2022). Captopril and losartan attenuate behavioural sensitization in mice chronically exposed to toluene. Behavioural brain research, 418113640. https://doi.org/10.1016/j.bbr.2021.113640
Oros-González, Alain, et al. "Captopril and losartan attenuate behavioural sensitization in mice chronically exposed to toluene." Behavioural brain research vol. 418 (2022): 113640. doi: https://doi.org/10.1016/j.bbr.2021.113640
Oros-González A, Gallardo-Ortíz IA, Montes S, Del Valle-Mondragón L, Páez-Martínez N. Captopril and losartan attenuate behavioural sensitization in mice chronically exposed to toluene. Behav Brain Res. 2022 Feb 10;418:113640. doi: 10.1016/j.bbr.2021.113640. Epub 2021 Oct 29. PMID: 34757000.
Copy Download .nbib Format: NLM
Chronic use of renin-angiotensin-aldosterone inhibitors in hypertensive COVID-19 patients: Results from a Spanish registry and meta-analysis.

Medicina clinica

Aparisi Á, Catalá P, Amat-Santos IJ, Marcos-Mangas M, López-Otero D, Veras C, López-Pais J, Cabezón-Villalba G, Cacho Antonio CE, Candela J, Antúnez-Muiños P, Gil JF, González Ferrero T, Rojas G, Pérez-Poza M, Uribarri A, Otero-García O, García-Granja PE, Jiménez Ramos V, Revilla A, Dueñas C, Gómez I, González-Juanatey JR, San Román JA.
PMID: 34088524
Med Clin (Barc). 2021 May 06; doi: 10.1016/j.medcli.2021.04.005. Epub 2021 May 06.

BACKGROUND: Hypertension is a prevalent condition among SARS-CoV-2 infected patients. Whether renin-angiotensin-aldosterone system (RAAS) inhibitors are beneficial or harmful is controversial.METHODS: We have performed a national retrospective, nonexperimental comparative study from two tertiary hospitals to evaluate the impact of...

Cite
Aparisi Á, Catalá P, Amat-Santos IJ, et al. Chronic use of renin-angiotensin-aldosterone inhibitors in hypertensive COVID-19 patients: Results from a Spanish registry and meta-analysis. Med Clin (Barc). 2021;doi: 10.1016/j.medcli.2021.04.005.
Aparisi, �. �., Catalá, P., Amat-Santos, I. J., Marcos-Mangas, M., López-Otero, D., Veras, C., López-Pais, J., Cabezón-Villalba, G., Cacho Antonio, C. E., Candela, J., Antúnez-Muiños, P., Gil, J. F., González Ferrero, T., Rojas, G., Pérez-Poza, M., Uribarri, A., Otero-García, O., García-Granja, P. E., Jiménez Ramos, V., Revilla, A., Dueñas, C., Gómez, I., González-Juanatey, J. R., & San Román, J. A. (2021). Chronic use of renin-angiotensin-aldosterone inhibitors in hypertensive COVID-19 patients: Results from a Spanish registry and meta-analysis. Medicina clinica, . https://doi.org/10.1016/j.medcli.2021.04.005
Aparisi, Álvaro, et al. "Chronic use of renin-angiotensin-aldosterone inhibitors in hypertensive COVID-19 patients: Results from a Spanish registry and meta-analysis." Medicina clinica vol. (2021). doi: https://doi.org/10.1016/j.medcli.2021.04.005
Aparisi Á, Catalá P, Amat-Santos IJ, Marcos-Mangas M, López-Otero D, Veras C, López-Pais J, Cabezón-Villalba G, Cacho Antonio CE, Candela J, Antúnez-Muiños P, Gil JF, González Ferrero T, Rojas G, Pérez-Poza M, Uribarri A, Otero-García O, García-Granja PE, Jiménez Ramos V, Revilla A, Dueñas C, Gómez I, González-Juanatey JR, San Román JA. Chronic use of renin-angiotensin-aldosterone inhibitors in hypertensive COVID-19 patients: Results from a Spanish registry and meta-analysis. Med Clin (Barc). 2021 May 06; doi: 10.1016/j.medcli.2021.04.005. Epub 2021 May 06. Spanish. PMID: 34088524; PMCID: PMC8101788.
Copy Download .nbib Format: NLM
Safety of Contemporary Heart Failure Therapy in Patients with Continuous-Flow Left Ventricular Assist Devices.

Journal of cardiac failure

Schnettler JK, Roehrich L, Just IA, Pergantis P, Stein J, Mueller M, Mulzer J, Knierim J, Falk V, Potapov FE, Schoenrath F.
PMID: 34157393
J Card Fail. 2021 Dec;27(12):1328-1336. doi: 10.1016/j.cardfail.2021.06.007. Epub 2021 Jun 19.

BACKGROUND: Limited data are available concerning the safety, optimal administration and benefits of contemporary heart failure therapy in patients after left ventricular assist device (LVAD) implantation.METHODS: Between 2015 and 2019, 257 patients underwent LVAD implantation and were included in...

Cite
Schnettler JK, Roehrich L, Just IA, et al. Safety of Contemporary Heart Failure Therapy in Patients with Continuous-Flow Left Ventricular Assist Devices. J Card Fail. 2021;27(12):1328-1336doi: 10.1016/j.cardfail.2021.06.007.
Schnettler, J. K., Roehrich, L., Just, I. A., Pergantis, P., Stein, J., Mueller, M., Mulzer, J., Knierim, J., Falk, V., Potapov, F. E., & Schoenrath, F. (2021). Safety of Contemporary Heart Failure Therapy in Patients with Continuous-Flow Left Ventricular Assist Devices. Journal of cardiac failure, 27(12), 1328-1336. https://doi.org/10.1016/j.cardfail.2021.06.007
Schnettler, Jessica Kristin, et al. "Safety of Contemporary Heart Failure Therapy in Patients with Continuous-Flow Left Ventricular Assist Devices." Journal of cardiac failure vol. 27,12 (2021): 1328-1336. doi: https://doi.org/10.1016/j.cardfail.2021.06.007
Schnettler JK, Roehrich L, Just IA, Pergantis P, Stein J, Mueller M, Mulzer J, Knierim J, Falk V, Potapov FE, Schoenrath F. Safety of Contemporary Heart Failure Therapy in Patients with Continuous-Flow Left Ventricular Assist Devices. J Card Fail. 2021 Dec;27(12):1328-1336. doi: 10.1016/j.cardfail.2021.06.007. Epub 2021 Jun 19. PMID: 34157393.
Copy Download .nbib Format: NLM
Oral angiotensin-converting enzyme inhibitors for treatment of delayed inflammatory reaction to dermal hyaluronic acid fillers following COVID-19 vaccination-a model for inhibition of angiotensin II-induced cutaneous inflammation.

JAAD case reports

Munavalli GG, Knutsen-Larson S, Lupo MP, Geronemus RG.
PMID: 33681439
JAAD Case Rep. 2021 Apr;10:63-68. doi: 10.1016/j.jdcr.2021.02.018. Epub 2021 Mar 02.

No abstract available.

Cite
Munavalli GG, Knutsen-Larson S, Lupo MP, et al. Oral angiotensin-converting enzyme inhibitors for treatment of delayed inflammatory reaction to dermal hyaluronic acid fillers following COVID-19 vaccination-a model for inhibition of angiotensin II-induced cutaneous inflammation. JAAD Case Rep. 2021;10:63-68doi: 10.1016/j.jdcr.2021.02.018.
Munavalli, G. G., Knutsen-Larson, S., Lupo, M. P., & Geronemus, R. G. (2021). Oral angiotensin-converting enzyme inhibitors for treatment of delayed inflammatory reaction to dermal hyaluronic acid fillers following COVID-19 vaccination-a model for inhibition of angiotensin II-induced cutaneous inflammation. JAAD case reports, 1063-68. https://doi.org/10.1016/j.jdcr.2021.02.018
Munavalli, Girish Gilly, et al. "Oral angiotensin-converting enzyme inhibitors for treatment of delayed inflammatory reaction to dermal hyaluronic acid fillers following COVID-19 vaccination-a model for inhibition of angiotensin II-induced cutaneous inflammation." JAAD case reports vol. 10 (2021): 63-68. doi: https://doi.org/10.1016/j.jdcr.2021.02.018
Munavalli GG, Knutsen-Larson S, Lupo MP, Geronemus RG. Oral angiotensin-converting enzyme inhibitors for treatment of delayed inflammatory reaction to dermal hyaluronic acid fillers following COVID-19 vaccination-a model for inhibition of angiotensin II-induced cutaneous inflammation. JAAD Case Rep. 2021 Apr;10:63-68. doi: 10.1016/j.jdcr.2021.02.018. Epub 2021 Mar 02. PMID: 33681439; PMCID: PMC7923909.
Copy Download .nbib Format: NLM
Involvement of the effect of renal hypoperfusion medications on vancomycin trough concentration: A secondary analysis using a retrospective observational data.

Basic & clinical pharmacology & toxicology

Hirai T, Hanada K, Iwamoto T, Itoh T.
PMID: 34396691
Basic Clin Pharmacol Toxicol. 2021 Nov;129(5):376-384. doi: 10.1111/bcpt.13646. Epub 2021 Sep 07.

This study examined the association between vancomycin (VCM) trough concentration and confounding factors including renal hypoperfusion medications which include angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, loop/thiazide diuretics, or non-steroidal anti-inflammatory drugs. This secondary analysis included patients aged >15 years who...

Cite
Hirai T, Hanada K, Iwamoto T, et al. Involvement of the effect of renal hypoperfusion medications on vancomycin trough concentration: A secondary analysis using a retrospective observational data. Basic Clin Pharmacol Toxicol. 2021;129(5):376-384doi: 10.1111/bcpt.13646.
Hirai, T., Hanada, K., Iwamoto, T., & Itoh, T. (2021). Involvement of the effect of renal hypoperfusion medications on vancomycin trough concentration: A secondary analysis using a retrospective observational data. Basic & clinical pharmacology & toxicology, 129(5), 376-384. https://doi.org/10.1111/bcpt.13646
Hirai, Toshinori, et al. "Involvement of the effect of renal hypoperfusion medications on vancomycin trough concentration: A secondary analysis using a retrospective observational data." Basic & clinical pharmacology & toxicology vol. 129,5 (2021): 376-384. doi: https://doi.org/10.1111/bcpt.13646
Hirai T, Hanada K, Iwamoto T, Itoh T. Involvement of the effect of renal hypoperfusion medications on vancomycin trough concentration: A secondary analysis using a retrospective observational data. Basic Clin Pharmacol Toxicol. 2021 Nov;129(5):376-384. doi: 10.1111/bcpt.13646. Epub 2021 Sep 07. PMID: 34396691.
Copy Download .nbib Format: NLM
Hydroxocobalamin or Methylene Blue for Vasoplegic Syndrome in Adult Cardiothoracic Surgery.

Journal of cardiothoracic and vascular anesthesia

Kram SJ, Kram BL, Cook JC, Ohman KL, Ghadimi K.
PMID: 34176677
J Cardiothorac Vasc Anesth. 2022 Feb;36(2):469-476. doi: 10.1053/j.jvca.2021.05.042. Epub 2021 May 27.

OBJECTIVE: To compare hydroxocobalamin and methylene blue for the treatment of vasopressor-refractory vasoplegic syndrome (VS) after adult cardiac surgery with cardiopulmonary bypass (CPB).DESIGN: A retrospective, propensity-matched, cohort study was performed. The primary endpoints were the percentage change in vasopressor...

Cite
Kram SJ, Kram BL, Cook JC, et al. Hydroxocobalamin or Methylene Blue for Vasoplegic Syndrome in Adult Cardiothoracic Surgery. J Cardiothorac Vasc Anesth. 2021;36(2):469-476doi: 10.1053/j.jvca.2021.05.042.
Kram, S. J., Kram, B. L., Cook, J. C., Ohman, K. L., & Ghadimi, K. (2022). Hydroxocobalamin or Methylene Blue for Vasoplegic Syndrome in Adult Cardiothoracic Surgery. Journal of cardiothoracic and vascular anesthesia, 36(2), 469-476. https://doi.org/10.1053/j.jvca.2021.05.042
Kram, Shawn J, et al. "Hydroxocobalamin or Methylene Blue for Vasoplegic Syndrome in Adult Cardiothoracic Surgery." Journal of cardiothoracic and vascular anesthesia vol. 36,2 (2022): 469-476. doi: https://doi.org/10.1053/j.jvca.2021.05.042
Kram SJ, Kram BL, Cook JC, Ohman KL, Ghadimi K. Hydroxocobalamin or Methylene Blue for Vasoplegic Syndrome in Adult Cardiothoracic Surgery. J Cardiothorac Vasc Anesth. 2022 Feb;36(2):469-476. doi: 10.1053/j.jvca.2021.05.042. Epub 2021 May 27. PMID: 34176677.
Copy Download .nbib Format: NLM
Comments on "DNA-binding activities of compounds acting as enzyme inhibitors, ion channel blockers and receptor binders.".

Chemico-biological interactions

Jaeschke H.
PMID: 34843691
Chem Biol Interact. 2022 Jan 05;351:109761. doi: 10.1016/j.cbi.2021.109761. Epub 2021 Nov 26.

I read with interest the article "DNA-binding activities of compounds acting as enzyme inhibitors, ion channel blockers and receptor binders" recently published in Chemico-Biological Interactions. The authors suggested that acetaminophen, one of the most used drugs worldwide, alkylates DNA...

Cite
Jaeschke H. Comments on "DNA-binding activities of compounds acting as enzyme inhibitors, ion channel blockers and receptor binders.". Chem Biol Interact. 2021;351:109761doi: 10.1016/j.cbi.2021.109761.
Jaeschke, H. (2022). Comments on "DNA-binding activities of compounds acting as enzyme inhibitors, ion channel blockers and receptor binders.". Chemico-biological interactions, 351109761. https://doi.org/10.1016/j.cbi.2021.109761
Jaeschke, Hartmut. "Comments on "DNA-binding activities of compounds acting as enzyme inhibitors, ion channel blockers and receptor binders."." Chemico-biological interactions vol. 351 (2022): 109761. doi: https://doi.org/10.1016/j.cbi.2021.109761
Jaeschke H. Comments on "DNA-binding activities of compounds acting as enzyme inhibitors, ion channel blockers and receptor binders.". Chem Biol Interact. 2022 Jan 05;351:109761. doi: 10.1016/j.cbi.2021.109761. Epub 2021 Nov 26. PMID: 34843691.
Copy Download .nbib Format: NLM
ACE inhibitor or ARB treatment among patients with diabetes and chronic kidney disease.

The American journal of managed care

Fried LF, Petruski-Ivleva N, Folkerts K, Schmedt N, Velentgas P, Kovesdy CP.
PMID: 34878753
Am J Manag Care. 2021 Dec;27(20):S360-S368. doi: 10.37765/ajmc.2021.88806.

OBJECTIVES: Many patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) experience a delay in treatment or fail to initiate treatment with guideline-recommended angiotensin-converting enzyme inhibitors (ACEis) or angiotensin receptor blockers (ARBs) after CKD diagnosis. This study...

Cite
Fried LF, Petruski-Ivleva N, Folkerts K, et al. ACE inhibitor or ARB treatment among patients with diabetes and chronic kidney disease. Am J Manag Care. 2021;27(20):S360-S368doi: 10.37765/ajmc.2021.88806.
Fried, L. F., Petruski-Ivleva, N., Folkerts, K., Schmedt, N., Velentgas, P., & Kovesdy, C. P. (2021). ACE inhibitor or ARB treatment among patients with diabetes and chronic kidney disease. The American journal of managed care, 27(20), S360-S368. https://doi.org/10.37765/ajmc.2021.88806
Fried, Linda F, et al. "ACE inhibitor or ARB treatment among patients with diabetes and chronic kidney disease." The American journal of managed care vol. 27,20 (2021): S360-S368. doi: https://doi.org/10.37765/ajmc.2021.88806
Fried LF, Petruski-Ivleva N, Folkerts K, Schmedt N, Velentgas P, Kovesdy CP. ACE inhibitor or ARB treatment among patients with diabetes and chronic kidney disease. Am J Manag Care. 2021 Dec;27(20):S360-S368. doi: 10.37765/ajmc.2021.88806. PMID: 34878753.
Copy Download .nbib Format: NLM
Handling unstable analytes: literature review and expert panel survey by the Japan Bioanalysis Forum Discussion Group.

Bioanalysis

Niwa M, Kondo A, Shibutani E, Tsuruta A, Shimada E, Hirata S, Fujino N, Maruyama S, Yagi R, Nishida H, Yoshimatsu H.
PMID: 34894755
Bioanalysis. 2022 Feb;14(3):169-185. doi: 10.4155/bio-2021-0229. Epub 2021 Dec 11.

Analyzing unstable small molecule drugs and metabolites in blood continues to be challenging for bioanalysis. Although scientific countermeasures such as immediate cooling, immediate freezing, addition of enzyme inhibitors, pH adjustment, dried blood spot or derivatization have been developed, selecting...

Cite
Niwa M, Kondo A, Shibutani E, et al. Handling unstable analytes: literature review and expert panel survey by the Japan Bioanalysis Forum Discussion Group. Bioanalysis. 2021;14(3):169-185doi: 10.4155/bio-2021-0229.
Niwa, M., Kondo, A., Shibutani, E., Tsuruta, A., Shimada, E., Hirata, S., Fujino, N., Maruyama, S., Yagi, R., Nishida, H., & Yoshimatsu, H. (2022). Handling unstable analytes: literature review and expert panel survey by the Japan Bioanalysis Forum Discussion Group. Bioanalysis, 14(3), 169-185. https://doi.org/10.4155/bio-2021-0229
Niwa, Makoto, et al. "Handling unstable analytes: literature review and expert panel survey by the Japan Bioanalysis Forum Discussion Group." Bioanalysis vol. 14,3 (2022): 169-185. doi: https://doi.org/10.4155/bio-2021-0229
Niwa M, Kondo A, Shibutani E, Tsuruta A, Shimada E, Hirata S, Fujino N, Maruyama S, Yagi R, Nishida H, Yoshimatsu H. Handling unstable analytes: literature review and expert panel survey by the Japan Bioanalysis Forum Discussion Group. Bioanalysis. 2022 Feb;14(3):169-185. doi: 10.4155/bio-2021-0229. Epub 2021 Dec 11. PMID: 34894755.
Copy Download .nbib Format: NLM
The PMDA Perspectives on New Oral Prolyl Hydroxylase Domain Enzyme Inhibitors for Renal Anemia.

Clinical pharmacology and therapeutics

Tanaka M, Ikuma M, Asakura W, Fujiwara Y.
PMID: 33993499
Clin Pharmacol Ther. 2022 Feb;111(2):358-361. doi: 10.1002/cpt.2275. Epub 2021 May 16.

No abstract available.

Cite
Tanaka M, Ikuma M, Asakura W, et al. The PMDA Perspectives on New Oral Prolyl Hydroxylase Domain Enzyme Inhibitors for Renal Anemia. Clin Pharmacol Ther. 2021;111(2):358-361doi: 10.1002/cpt.2275.
Tanaka, M., Ikuma, M., Asakura, W., & Fujiwara, Y. (2022). The PMDA Perspectives on New Oral Prolyl Hydroxylase Domain Enzyme Inhibitors for Renal Anemia. Clinical pharmacology and therapeutics, 111(2), 358-361. https://doi.org/10.1002/cpt.2275
Tanaka, Mototsugu, et al. "The PMDA Perspectives on New Oral Prolyl Hydroxylase Domain Enzyme Inhibitors for Renal Anemia." Clinical pharmacology and therapeutics vol. 111,2 (2022): 358-361. doi: https://doi.org/10.1002/cpt.2275
Tanaka M, Ikuma M, Asakura W, Fujiwara Y. The PMDA Perspectives on New Oral Prolyl Hydroxylase Domain Enzyme Inhibitors for Renal Anemia. Clin Pharmacol Ther. 2022 Feb;111(2):358-361. doi: 10.1002/cpt.2275. Epub 2021 May 16. PMID: 33993499.
Copy Download .nbib Format: NLM
Showing 1585 to 1596 of 1616 entries